Preventing HIV transmission from mothers to newborns using a new treatment method.
AAV Delivered CCR5 Blockade for Prevention of Mother-to-Child HIV Transmission.
This study is testing a new way to help prevent mothers from passing HIV to their babies by using a special treatment that delivers an antibody to newborns, and it's being done in baby macaques to see if it could work for humans, aiming to find a safer option than current medications.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Oregon Health & Science University NIH-funded |
| Lab location | 1 site (Portland, United States) |
| Project ID | NIH-10670864 on NIH RePORTER |
What this research studies
This research investigates a novel approach to prevent mother-to-child transmission of HIV by using a gene therapy technique. It focuses on delivering a specific antibody, Leronlimab, through a viral vector to newborns, aiming to provide long-term protection against HIV infection. The study will assess the effectiveness of this treatment in infant macaques, which serves as a model for understanding its potential in humans. By exploring this method, the research seeks to offer a safer alternative to current antiretroviral treatments that can have harmful side effects for newborns.
Who could benefit from this research
Good fit: Ideal candidates for this research are expectant mothers living with HIV, particularly in regions with limited access to traditional antenatal care.
Not a fit: Patients who are not pregnant or do not have HIV may not receive any benefit from this research.
Why it matters
Potential benefit: If successful, this research could significantly reduce the risk of HIV transmission from mothers to their infants, leading to healthier outcomes for newborns.
How similar studies have performed: Previous research has shown promise in using similar gene therapy approaches for HIV prevention, indicating potential for success in this novel application.
Where this research is happening
Portland, United States
- Oregon Health & Science University — Portland, United States (Active)
Researchers
- Principal investigator: Sacha, Jonah B. — Oregon Health & Science University
- Study coordinator: Sacha, Jonah B.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.